Adrenergic receptors blockade alleviates dexamethasone-induced neurotoxicity in adult male Wistar rats: Distinct effects on β-arrestin2 expression and molecular markers of neural injury
DARU Journal of Pharmaceutical Sciences - Trang 1-12 - 2023
Tóm tắt
Dexamethasone-induced neurotoxicity has been previously reported. However, the molecular mechanisms are still not completely understood. The current work aimed to investigate the modulatory effects of α- and β-adrenergic receptors on dexamethasone-induced neurotoxicity in rats focused on changes in β-arrestin2 and molecular markers of neural injury in cerebral cortex. Male Wistar rats were subcutaneously injected with dexamethasone (10 mg/kg/day) for 7 days to induce neural injury in the cerebral cortex. The experiment involved 5 groups: control, dexamethasone, carvedilol, propranolol, and doxazosin. In the last 3 groups, drugs were given 2 hours before dexamethasone injection. At the end of experiment, brain samples were collected for measurement of brain derived neurotrophic factor (BDNF), glial fibrillary acidic protein (GFAP), kinase activity of protein kinase B (Akt), diacylglycerol (DAG), α-smooth muscle actin (α-SMA), Smad3, β-amyloid and phospho-tau protein levels in addition to histopathological examination of brain tissue using hematoxylin-eosin, Nissl, and Sirius red stains. Moreover, β-arrestin2 levels in the cerebral cortex were measured using immunohistochemical examination. Dexamethasone slightly reduced brain weight and significantly decreased BDNF, Akt kinase activity and β-arrestin2 but markedly induced degeneration of cortical neurons and significantly increased GFAP, DAG, α-SMA, Smad3, β-amyloid and phospho-tau protein levels compared to controls. Carvedilol, propranolol, and doxazosin reversed all dexamethasone-induced molecular changes and slightly ameliorated the histopathological changes. Carvedilol significantly increased brain weight and β-arrestin2 levels compared to dexamethasone, propranolol, and doxazosin groups. blocking α- and/or β-adrenergic receptors alleviate dexamethasone-induced neurotoxicity despite their distinct effects on β-arrestin2 levels in the cerebral cortex.
Tài liệu tham khảo
King A, Elmaraghy C, Lind M, Tobias JD. A review of dexamethasone as an adjunct to adenotonsillectomy in the pediatric population. J Anesth. 2020;34:445–52.
Kapugi M, Cunningham K. Corticosteroids. Orthop Nurs. 2019;38(5):336–9.
Raghunath A, Chandrasekara SD, Anthony SN, Markman B. Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting–a systematic review and meta-analysis. Crit Rev Oncol/Hematol. 2020;152:103012.
Boussios ST, Cooke D, Hayward C, Kanellos FS, Tsiouris AK, Chatziantoniou AA, Zakynthinakis-Kyriakou N, Karathanasi A. Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges. Anticancer Res. 2018;38(9):4987–97.
Skeoch GD, Tobin MK, Khan S, Linninger AA, Mehta AI. Corticosteroid treatment for metastatic spinal cord compression: a review. Global Spine J. 2017;7(3):272–9.
Feng Y, Kumar P, Wang J, Bhatt AJ. Dexamethasone but not the equivalent doses of hydrocortisone induces neurotoxicity in neonatal rat brain. Pediatr Res. 2015;77(5):618–24.
Baud O, Zupan V, Lacaze-Masmonteil TH, Dehan M. Neurological adverse effects of early postnatal dexamethasone in very preterm infants. Arch Dis Child Fetal Neonatal Ed. 1999;80(2):F158.
Hertz L, Lovatt D, Goldman SA, Nedergaard M. Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca2+] i. Neurochem Int. 2010;57(4):411–20.
Perez DM. α1-Adrenergic receptors in neurotransmission, synaptic plasticity, and cognition. Front Pharmacol. 2020;11:581098.
Gao V, Suzuki A, Magistretti PJ, Lengacher S, Pollonini G, Steinman MQ, Alberini CM. Astrocytic β2-adrenergic receptors mediate hippocampal long-term memory consolidation. Proc Natl Acad Sci USA. 2016;113(30):8526–31.
Feng X, Wu CY, Burton FH, Loh HH, Wei LN. β-arrestin protects neurons by mediating endogenous opioid arrest of inflammatory microglia. Cell Death Differ. 2014;21(3):397–406.
Park SW, Seo MK, Cho HY, Lee JG, Lee BJ, Seol W, Kim YH. Differential effects of amisulpride and haloperidol on dopamine D2 receptor-mediated signaling in SH-SY5Y cells. Neuropharmacology. 2011;61(4):761–9.
Wang WY, Wu XM, Jia LJ, Zhang HH, Cai F, Mao H, Xu WC, Chen L, Zhang J, Hu SF. Beta-arrestin1 and 2 differently modulate metabotropic glutamate receptor 7 signaling in rat developmental sevoflurane-induced neuronal apoptosis. Neuroscience. 2016;313:199–212.
Ibrahim WS, Ibrahim IA, Mahmoud MF, Mahmoud AA. Carvedilol diminishes cardiac remodeling induced by high-fructose/high-fat diet in mice via enhancing cardiac β-arrestin2 signaling. J Cardiovasc Pharmacol Ther. 2020;25(4):354–63.
Klein LA. Propranolol protection in acute renal failure. Investig Urol. 1978;15(5):401–3.
Mohamed RM, Ahmad EA, Omran BH, Sakr AT, Ibrahim IA, Mahmoud MF, El-Naggar ME. Mitigation of dexamethasone-induced nephrotoxicity by modulating the activity of adrenergic receptors: Implication of Wnt/β-arrestin2/β-catenin pathway. Life Sci. 2022;293:120304.
Lysko PG, Lysko KA, Yue TL, Webb CL, Gu JL, Feuerstein G. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke. 1992;23(11):1630–5.
Magadmi RM, Alsulaimani MA, Al-Rafiah AR, Ahmad MS, Esmat A. Carvedilol exerts neuroprotective effect on rat model of diabetic neuropathy. Front Pharmacol. 2021;12:613634.
Kirk C, Tan Z, McDonnell JF, Perlman J, Bu P. The neuroprotective effect of propranolol against retinal degeneration in a mouse model of light injury. Investig Ophthalmol Vis Sci. 2021;62(8):2724.
Coelho BP, Gaelzer MM, dos Santos Petry F, Hoppe JB, Trindade VM, Salbego CG, Guma FT. Dual effect of doxazosin: anticancer activity on SH-SY5Y neuroblastoma cells and neuroprotection on an in vitro model of Alzheimer’s disease. Neuroscience. 2019;404:314–25.
El-Fayoumi SH, Mahmoud AA, Fahmy A, Ibrahim IA. Effect of omega-3 fatty acids on glucose homeostasis: role of free fatty acid receptor 1. Naunyn. Schmiedebergs Arch Pharmacol. 2020;393:1797–808.
Mahendran P, Devi CS. Effect of Garcinia cambogia extract on lipids and lipoprotein composition in dexamethasone administered rats. Indian J Physiol Pharmacol. 2001;45(3):345–50.
Okamoto H, Hori M, Matsuzaki M, Tsutsui H, Yamazaki T, Nagai R, Yoshikawa T, Fujio Y, Nonen S, Azuma J, Izumi T. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. Int J Cardiol. 2013;164(2):238–44.
Wang D, Wang Q, Yin J, Dong R, Wang Q, Du X, Lu J. Combined administration of propranolol+ AG490 offers better effects on portal hypertensive rats with cirrhosis. J Gastroenterol Hepatol. 2016;31(5):1037–44.
James IM, Yogendran L, McLaughlin K, Munro C. Blood pressure lowering and cerebral blood flow: a comparison of the effects of carvedilol and propranolol on the cerebral circulation in hypertensive patients. J Cardiovasc Pharmacol. 1992;19:S40-3.
Ohta K, Kim S, Iwao H. Role of angiotensin-converting enzyme, adrenergic receptors, and blood pressure in cardiac gene expression of spontaneously hypertensive rats during development. Hypertension. 1996;28(4):627–34.
Cox DA, Leader JP, Milson JA, Singleton W. The antihypertensive effects of doxazosin: a clinical overview. Br J Clin Pharmacol. 1986;21(S1):83S-90S.
Hsu SM, Raine L. Protein A, avidin, and biotin in immunohistochemistry. J Histochem Cytochem. 1981;29:1349–53.
Schisterman EF, Vexler A. To pool or not to pool, from whether to when: applications of pooling to biospecimens subject to a limit of detection. Paediatr Perinat Epidemiol. 2008;22(5):486–96.
Evdokimov DV, Abramets II. Neurotoxic effect of dexamethasone: weakening upon the action of antidepressants. Neurophysiology. 2008;40(4):261–9.
Lanshakov DA, Sukhareva EV, Kalinina TS, Dygalo NN. Dexamethasone-induced acute excitotoxic cell death in the developing brain. Neurobiol Dis. 2016;91:1–9.
Wolkowitz OM, Lupien SJ, Bigler ED. The “steroid dementia syndrome”: a possible model of human glucocorticoid neurotoxicity. Neurocase. 2007;13(3):189–200.
Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;363.
Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T. Role for Akt3/protein kinase Bγ in attainment of normal brain size. Mol Cell Biol. 2005;25(5):1869–78.
Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421–43.
Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi EJ, Moeton M, Freriks M, Mizee MR, Hol EM. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer’s disease. Neurobiol Aging. 2014;35(3):492–510.
Shirai Y, Kouzuki T, Kakefuda K, Moriguchi S, Oyagi A, Horie K, Morita SY, Shimazawa M, Fukunaga K, Takeda J, Saito N. Essential role of neuron-enriched diacylglycerol kinase (DGK), DGKβ in neurite spine formation, contributing to cognitive function. PLoS One. 2010;5(7):e11602.
Wang J, Zohar R, McCulloch CA. Multiple roles of α-smooth muscle actin in mechanotransduction. Exp Cell Res. 2006;312(3):205–14.
Moreels M, Vandenabeele F, Dumont D, Robben J, Lambrichts I. Alpha-smooth muscle actin (α-SMA) and nestin expression in reactive astrocytes in multiple sclerosis lesions: potential regulatory role of transforming growth factor-beta 1 (TGF-β1). Neuropathol Appl Neurobiol. 2008;34(5):532–46.
Hutter-Schmid B, Humpel C. Alpha-smooth muscle actin mRNA and protein are increased in isolated brain vessel extracts of Alzheimer mice. Pharmacology. 2016;98(5–6):251–60.
Hamby ME, Hewett JA, Hewett SJ. Smad3-dependent signaling underlies the TGF-β1-mediated enhancement in astrocytic iNOS expression. Glia. 2010;58(11):1282–91.
Nisbet RM, Götz J. Amyloid-β and Tau in Alzheimer’s disease: novel pathomechanisms and non-pharmacological treatment strategies. J Alzheimers Dis. 2018;64(s1):S517-27.
Sun KH, Chang Y, Reed NI, Sheppard D. α-Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGFβ activation or collagen production across multiple models of organ fibrosis. Am J Physiol Cell Mol Physiol. 2016;310(9):L824-36.
Lepelletier FX, Mann DM, Robinson AC, Pinteaux E, Boutin H. Early changes in extracellular matrix in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2017;43(2):167–82.
Sun Y, Xu S, Jiang M, Liu X, Yang L, Bai Z, Yang Q. Role of the extracellular matrix in Alzheimer’s disease. Front Aging Neurosci. 2021;13:707466.
Thathiah A, Horré K, Snellinx A, Vandewyer E, Huang Y, Ciesielska M, De Kloe G, Munck S, De Strooper B. β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer’s disease. Nat Med. 2013;19(1):43–9.
Wood H. Arrestin’Alzheimer disease progression? β-arrestin 2 is a potential therapeutic target. Nat Rev Neurol. 2013;9(2):60.
Poirier L, Tobe SW. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30(5):S9-15.
de Sousa CN, Medeiros ID, Vasconcelos GS, de Aquino GA, Cysne Filho FM, de Almeida Cysne JC, Macêdo DS, Vasconcelos SM. Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress. Psychopharmacology. 2022;1:1–5.
Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian X, Lamparello A, Subnani R, Ferruzzi M, Pavlides C, Ho L. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease. Neurobiol Aging. 2011;32(12):2321-e1.
Laurens C, Abot A, Delarue A, Knauf C. Central effects of beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier. Front Neurosci. 2019;13:33.
Ibrahim WS, Ahmed HM, Mahmoud AA, Mahmoud MF, Ibrahim IA. Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, highfat diet-fed mice: Comparative study with metformin. Life Sci. 2021;286:120055.
Dobarro M, Gerenu G, Ramírez MJ. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer’s transgenic mice. Int J Neuropsychopharmacol. 2013;16(10):2245–57.
Gaelzer MM, Coelho BP, De Quadros AH, Hoppe JB, Terra SR, Guerra MC, Usach V, Guma FC, Gonçalves CA, Setton-Avruj P, Battastini AM. Phosphatidylinositol 3-kinase/AKT pathway inhibition by doxazosin promotes glioblastoma cells death, upregulation of p53 and triggers low neurotoxicity. PLoS One. 2016;11(4):e0154612.